Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Purpose: Positron emission tomography (PET) with both 2′-deoxy-2′-[18 F]fluoro-d-glucose (FDG) and 3′-[18 F]fluoro-3′-deoxy-l-thymidine (FLT) was evaluated with respect to the accuracy of early prediction of nonprogression following erlotinib therapy, independent from epidermal growth factor receptor (EGFR) mutational status, in patients with previously untreated advanced non–small-cell lung cancer (NSCLC). Patients and Methods: Thirty-four patients with untreated stage IV NSCLC were evaluated in this phase II trial. Changes in FDG and FLT uptake after 1 (early) and 6 (late) weeks of erlotinib treatment were compared with nonprogression measured by computed tomography after 6 weeks of treatment, progression-free survival (PFS), and overall survival (OS). Results: Changes in FDG uptake after 1 week of therapy predicted nonprogression after 6 weeks of therapy with an area under the receiver operating characteristic curve of 0.75 (P = .02). Furthermore, patients with an early metabolic FDG response (cutoff value: 30% reduction in the peak standardized uptake value) had significantly longer PFS (hazard ratio [HR], 0.23; 95% CI, 0.09 to 0.59; P = .002) and OS (HR, 0.36; 95% CI, 0.13 to 0.96; P = .04). Early FLT response also predicted significantly longer PFS (HR, 0.31; 95% CI, 0.10 to 0.95; P = .04) but not OS and was not predictive for nonprogression after 6 weeks of therapy. Conclusion: Early FDG-PET predicts PFS, OS, and nonprogression after 6 weeks of therapy with erlotinib in unselected, previously untreated patients with advanced NSCLC independent from EGFR mutational status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Cappuzzo, F., Ciuleanu, T., Stelmakh, L., Cicenas, S., Szczésna, A., Juhász, E., Esteban, E., Molinier, O., Brugger, W., Melezínek, I., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70112-1 · Cited by 1,186
Cited by
PET in the management of locally advanced and metastatic NSCLC
Grootjans, W., de Geus-Oei, L.-F., Troost, E. G. C., Visser, E. P., Oyen, W. J. G., & Bussink, J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.75 · Cited by 97
Vanderhoek, M., Perlman, S. B., & Jeraj, R. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.113332 · Cited by 47
“In addition, PET response thresholds of 630% (as in PERCIST) are supported by a variety of other 18F-FLT PET–based response assessment studies (25,38,39).”
BackgroundFledelius, J., Khalil, A., Hjorthaug, K., & Frøkiær, J. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0223-6 · Cited by 24
Ni, J., Weng, L., Liu, Y., Sun, Z., Bai, C., & Wang, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6022 · Cited by 23
Agüloğlu, N., Akyol, M., Kömek, H., & Katgı, N. (2022) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/mirt.galenos.2022.24650 · Cited by 4
“Several studies (28,29) to date have evaluated the significance of (18)F-FDG uptake in the prediction of EGFR mutations in NSCLC, some of which have focused on SUV max , identifying low SUV max as an independent predictor of EGFR mutations (30,31,32,33); while in another study, it was emphasized that a high SUV max wa…”
Background
Metadata
- Authors
- Zander, T., Scheffler, M., Nogova, L., Kobe, C., Engel-Riedel, W., Hellmich, M., Papachristou, I., Toepelt, K., Draube, A., Heukamp, L., Buettner, R., Ko, Y. D., Ullrich, R. T., Smit, E., Boellaard, R., Lammertsma, A. A., Hallek, M., Jacobs, A. H., Schlesinger, A., Schulte, K., Querings, S., Stoelben, E., Neumaier, B., Thomas, R. K., Dietlein, M., & Wolf, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-05-01
- Volume
- 29
- Issue
- 13
- Pages
- 1701-1708
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2053846938
- Cited by
- 170
- References
- 5
- FWCI
- 20.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.